Brief: FDA Approves Ziftomenib For Relapsed Or Refractory Acute Myeloid Leukemia With A NPM1 Mutation

Kura Oncology

13/11/2025 15:21

Nov 13 (Reuters) - FDA :

FDA: APPROVES ZIFTOMENIB FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH A NPM1 MUTATION

Source text: [ID:]

Further company coverage: KURA.O

 ((Reuters.Briefs@thomsonreuters.com;))